Artículos por temáticas

Mechanisms of synaptic dysfunction and excitotoxicity in Huntington's disease.

Sepers MD, Raymond LA.

Drug Discov Today. 2014 Jul;19(7):990-6. doi: 10.1016/j.drudis.2014.02.006. Review.

Cannabinoid receptor CB2 is expressed on vascular cells, but not astroglial cells in the post-mortem human Huntington's disease brain.

Dowie MJ, Grimsey NL, Hoffman T, Faull RL, Glass M.

J Chem Neuroanat. 2014 Sep;59-60:62-71. doi: 10.1016/j.jchemneu.2014.06.004.

Preclinical and clinical investigations of mood stabilizers for Huntington's disease: what have we learned?

Scheuing L, Chiu CT, Liao HM, Linares GR, Chuang DM.

Int J Biol Sci. 2014 Sep 10;10(9):1024-38. doi: 10.7150/ijbs.9898. Review.

An exploration of the experience of Huntington's disease in family dyads: an interpretative phenomenological analysis.

Maxted C, Simpson J, Weatherhead S.

J Genet Couns. 2014 Jun;23(3):339-49. doi: 10.1007/s10897-013-9666-3.

Insulin and IGF-1 improve mitochondrial function in a PI-3K/Akt-dependent manner and reduce mitochondrial generation of reactive oxygen species in Huntington's disease knock-in striatal cells.

Ribeiro M, Rosenstock TR, Oliveira AM, Oliveira CR, Rego AC.

Free Radic Biol Med. 2014 Sep;74:129-44. doi: 10.1016/j.freeradbiomed.2014.06.023.

Isolated Chorea Associated with LGI1 Antibody.

Ramdhani RA, Frucht SJ.

Tremor Other Hyperkinet Mov (N Y). 2014 Jan 8;4. pii: tre-04-213-4821-1. doi: 10.7916/D8MG7MFC.

Differential nuclear localization of complexes may underlie in vivo intrabody efficacy in Huntington's disease.

Butler DC, Snyder-Keller A, De Genst E, Messer A.

Protein Eng Des Sel. 2014 Oct;27(10):359-63. doi: 10.1093/protein/gzu041.

Reduced automatic frontal response to auditory deviance in Huntington's disease as indexed by magnetic mismatch negativity.

Cheng CH, Soong BW, Hsu WY, Lin YY.

J Clin Neurosci. 2014 Oct;21(10):1773-8. doi: 10.1016/j.jocn.2014.01.019.

White matter connectivity reflects clinical and cognitive status in Huntington's disease.

Poudel GR, Stout JC, Domínguez D JF, Salmon L, Churchyard A, Chua P, Georgiou-Karistianis N, Egan GF.

Neurobiol Dis. 2014 May;65:180-7. doi: 10.1016/j.nbd.2014.01.013.

The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease.

Russell DS, Barret O, Jennings DL, Friedman JH, Tamagnan GD, Thomae D, Alagille D, Morley TJ, Papin C, Papapetropoulos S, Waterhouse RN, Seibyl JP, Marek KL.

JAMA Neurol. 2014 Dec;71(12):1520-8. doi: 10.1001/jamaneurol.2014.1954.

Results of the citalopram to enhance cognition in Huntington disease trial.

Beglinger LJ, Adams WH, Langbehn D, Fiedorowicz JG, Jorge R, Biglan K, Caviness J, Olson B, Robinson RG, Kieburtz K, Paulsen JS.

Mov Disord. 2014 Mar;29(3):401-5. doi: 10.1002/mds.25750.

Feasibility of Huntington disease trials in the disease prodrome.

McCusker EA, Myers RH.

Neurology. 2014 Mar 11;82(10):824-5. doi: 10.1212/WNL.0000000000000197. No abstract available.

From mild ataxia to huntington disease phenocopy: the multiple faces of spinocerebellar ataxia 17.

Koutsis G, Panas M, Paraskevas GP, Bougea AM, Kladi A, Karadima G, Kapaki E.

Case Rep Neurol Med. 2014;2014:643289. doi: 10.1155/2014/643289.

Pulmonary function in patients with Huntington's disease.

Reyes A, Cruickshank T, Ziman M, Nosaka K.

BMC Pulm Med. 2014 May 26;14:89. doi: 10.1186/1471-2466-14-89.

Autopsy case of concurrent Huntington's disease and neurofibromatosis type 1.

Kawakami I, Katsuse O, Aoki N, Togo T, Suzuki K, Isojima D, Kondo D, Iseki E, Kosaka K, Akiyama H, Hirayasu Y.

Psychogeriatrics. 2014 Mar;14(1):81-6. doi: 10.1111/psyg.12040.